Panitumumab and Bortezomib for Patients With Advanced Colorectal Cancer

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

December 31, 2011

Primary Completion Date

February 28, 2014

Study Completion Date

February 28, 2014

Conditions
Colorectal Cancer
Interventions
DRUG

Panitumumab and bortezomib

"Panitumumab 6 mg/kg IV over 60 minutes on Day -14 (first cycle only), then Day 1 and 15 of each 28-day cycle.~Bortezomib will be administered in escalating doses until the maximum tolerated dose is determined and then at the maximum tolerated dose as an IV bolus injection over 3-5 seconds on Day 1, 8, and 15 of each 28-day cycle."

Trial Locations (1)

20007

Georgetown Lombardi Comprehensive Cancer Center, Washington D.C.

Sponsors
All Listed Sponsors
collaborator

Millennium Pharmaceuticals, Inc.

INDUSTRY

lead

Georgetown University

OTHER